Preclinical feature articles
-
Former Big Pharma R&D Exec Shares Thoughts On Outsourcing
5/2/2013
Jim Hauske is President and founder of Sensor Pharmaceuticals, a company focused on the nexus of inflammation and metabolic disease. A virtual company, Sensor has established business relationships with AMRI, Absorption Systems, MPI, RenaSci, Ricerca and SciLucent. These relationships provide the means to synthesize, screen and assess, in disease models, new chemical entities designed by Sensor. The company has pre-clinical compounds representing several chemo types versus GPR119, GPR120 and TLR-4. All these molecules have demonstrated in vivo activity in relevant animal disease models.
-
Outsourcing Insights From The President Of A Virtual Drug Discovery Company
4/16/2013
Carolyn Green, is the President and Director for Atreaon, Inc., a privately held biopharmaceutical company developing a novel engineered protein called Atsttrin, for the treatment of inflammatory diseases such as rheumatoid arthritis. Having recently completed a $20 million Series A financing to support the pre-clinical development of Atsttrin, Green took time out from her busy schedule to share some of her thoughts and insights regarding the outsourcing of clinical research.
-
A Chief Scientific Officer’s Opinion On Clinical Outsourcing
4/16/2013
Dr. Kenneth Burhop is the chief scientific officer of Sangart Inc., a biopharmaceutical company that engages in the research, development, and commercialization of oxygen therapeutics. He joined Sangart in January 2011, after serving as the global scientific lead/CSO for Baxter Healthcare’s Medication Delivery division and VP of R&D for Baxter's Biopharmaceutical Technologies business, including the company’s second generation recombinant hemoglobin program. He has authored over forty publications, more than seventy abstracts, several book chapters, and has been invited to speak at various international meetings and symposia, and is a recognized international expert in the field of hemoglobin therapeutics. Burhop shares his opinions on clinical outsourcing.
-
Outsourcing Perceptions From The CEO Of An Early Stage Start-Up
4/1/2013
Leslie Williams is President, CEO, and founder of ImmusanT, Inc., an early stage company focused on peptide treatments for auto-immune diseases. Williams has over 20 years of industry experience in healthcare, management, commercial product development and marketing. Williams took time out from her managerial duties to share her perceptions on outsourcing and working with CROs.
-
Outsourcing Insights From The Executive Director Of Medical Research Operations For Purdue Pharma
4/1/2013
Dr. Mitchell Katz, Ph.D. is the executive director of medical research operations responsible for leading activities across all clinical programs for Purdue Pharma. He has 26 years’ experience in the pharmaceutical and biotech industries, including preclinical research, pharmaceutical operations, and regulatory affairs. Katz, a key opinion leader within the clinical trial space, often speaking at key industry events such as Partnerships in Clinical Trials, and DIA. He recently shared his insights regarding outsourcing in the clinical universe.
-
Former Acorda Chief Medical Officer Discusses Benefits And Pitfalls Of Outsourcing
3/18/2013
Dr. Thomas C. Wessel, former chief medical officer for Acorda Therapeutics, recently shares his expertise acquired from working with the clinical development and operations, regulatory affairs, biostatistics, data management and drug safety functions.
-
Increased Adoption Of iPSC-Derived Human Cells For Use In Drug Discovery And Toxicity Testing
10/1/2012
Traditionally, discovering a pharmacological therapy for a disease involves first investigating the underlying biological processes of that condition and then identifying drug candidates that interfere with those processes. From here, the most promising compounds are advanced to pre-clinical and clinical development. The goal of this “bench to bedside” approach is to translate bench research to point-of-care patient outcomes as quickly and safely as possible. With dwindling drug pipelines, pharmaceutical companies need new approaches that can re-energize their discovery efforts. By Chris Parker, Vice President and Chief Commercial Officer, Cellular Dynamics International
-
March Madness - Coast To Coast To Attend SOT And DCAT
3/20/2012
I recently had the opportunity to attend two different events — the Society of Toxicology ToxExpo (SOT) and the Drug, Chemical, and Associated Technologies Week (DCAT). By Rob Wright, Chief Editor, Life Science Leader magazine